| Objective：The purpose of this study is to evaluate the immunophenotypes and Th1/Th2in peripheral blood from patients with hepatocellular carcinoma. Explore the effect ofDC-CIK immunotherapy on the immune function of hepatocellular carcinoma patients.Methods：In2010-2012,66cases of hepatocellular carcinoma patients were admitted(postoperative residual), Child-puph class A,41cases of male and27cases of female,45-78years old. All the diagnosis of patients were based on clinical symptoms, B ultrasound andpathology inspection. Control group of26patients, including16males and10females frommedical staff are the healthy population, aged66-65years old. Flow cytometry lymphocytephenotype CD3, CD4, CD8, CD56, CD19and Th1/Th2immune status in peripheral blood ofeach group were observed by FCM.Results：Total CD3+T lymphocytes, CD3+CD4+T cells, NK cells, CD4/CD8ratios inthe peripheral blood of patients with primary liver cancer were lower than the normal healthycontrol group. The percentage of CD3+T-lymphocyte and CD3+CD4+T cell were (54.51±6.56)%and (27.98±7.24)%, with significant difference (P <0.05) compared with normalhealthy control. Th2cells of patients with primary liver has a higher percentage (5.90±2.10)%, compared with the normal healthy group (p <0.05). After treatments of DC–CIKimmunotherapy, percentage of CD3+T lymphocyte (65.91±5.34)%and CD3+CD4+T cell(37.79±6.22)%were significantly increased (p <0.05). After treatment, the proportion of Th1cells was (13.30±4.60)%, which were higher compare to the before treatment data (p <0.05).Conclusions： The immune functions of hepatocellular carcinoma patients weredecreased and could be enhanced by DC-CIK immunotherapy. The flow cytometry is a rapid,sensitive and accurate method to detect the immunological function of patients withhepatocellular carcinoma and is an effective evaluation method of DC-CIK therapy. |
PDF Full Text Request